整合素α4在难治复发急性淋巴细胞白血病中的研究进展  

Research Advances of Integrin Alpha 4 in Drug Resistant or Relapsed Acute Lymphoblastic Leukemia

作　　者：徐倚琪 吴学东[1] 阮永胜[1] 

机构地区：[1]南方医科大学南方医院儿科,广东广州

出　　处：《亚洲儿科病例研究》2018年第4期35-39,共5页Asian Case Reports in Pediatrics

基　　金：南方医科大学留学回国培育项目LX2017N005。

摘　　要：当下难治复发急性淋巴细胞白血病(ALL)不管在成人还是儿童中均面临着较差预后的治疗挑战,而整合素α4基本表达于所有淋巴细胞表面,且是参与细胞粘附介导耐药(CAM-DR)机制中重要组成部分,故本文将从CAM-DR在难治复发ALL中的作用、整合素α4介导的CAM-DR效应、拮抗整合素α4在治疗难治复发ALL的意义三方面展开综述,为治疗难治复发ALL病人提供一种新的治疗思路。Chemotherapeutic drug resistance or relapse in acute lymphoblastic leukemia (r/r ALL) is a chal-lenging problem, resulting in poor prognosis. Integrin alpha 4 plays a critical role in mechanism of cell adhesion-mediated drug resistance (CAM-DR), while expressing on most leukocyte surface broadly including lymphoblastic leukemia cell. We here review the mechanism of CAM-DR in r/r ALL, the role of integrin alpha 4 in mechanism of CAM-DR and the targeting of integrin alpha 4 as a novel strategy for treatment of r/r ALL.

关 键 词：整合素Α4 急性淋巴细胞白血病 细胞粘附介导的药物耐药性 

分 类 号：R73[医药卫生—肿瘤]